TrialDiabetes, obesity & metabolism2020

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.

Chantal Mathieu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.